PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges

Poly(ADP-ribose) polymerase inhibitors (PARPi) have reshaped therapy for advanced prostate cancer, yet durable benefit remains concentrated in BRCA1/2-altered tumors, especially BRCA2, and most responders eventually relapse. Here, we frame PARPi response and resistance through a unifying model in wh...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Takashi Matsuoka, Shusuke Akamatsu, Christopher J. Ong, Martin E. Gleave, Yuzhuo Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-03-01
Edice:	Cells
Témata:	PARP inhibitors homologous recombination repair (HRR) BRCA1/2 androgen receptor pathway inhibitors (ARPI) androgen deprivation therapy (ADT) metastatic castration-sensitive prostate cancer (mCSPC)
On-line přístup:	https://www.mdpi.com/2073-4409/15/7/588
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!